Cannabis Demand Remains Healthy Despite COVID-19 Challenges
Ryan Allway
June 25th, 2020
App, Exclusive, News, Top Story
Oregon cannabis sales topped $100 million for the first time since legalization despite the impact of COVID-19, according to the Oregon Liquor Control Commission. While COVID-19 has impacted nearly every part of the economy, cannabis businesses have remained open as essential businesses in the United States and other parts of the world.
Canadian demand is also expected to be robust. While the country closed many retail shops, the system has long relied on mail delivery as a primary means of distribution. The re-opening of retail outlets over the past few weeks could also help pave the way for an increase in revenue as customers start to venture back out into society.
In Europe, pharmacy-based distribution models may limit demand to some extent, but the region still faces a severely constrained supply and enormous pent-up demand. Prohibition Partners estimates that the market could be worth north of $136 billion by 2028, or about four times larger than the projected value of the U.S. cannabis market.
Click here to learn more about investing in the Israeli cannabis market
Gearing Up for a Rebound
The Israeli Ministry of Economy signed a Free Export Order on May 13, 2020 that implements an earlier decision to approve cannabis exports. The order is scheduled to go into effect in June and will allow licensed producers of medical cannabis in Israel to apply for an export permit to ship products to international markets—including Europe.
“Supply in both the domestic and European markets is lagging behind demand, especially in Europe, as more countries work on less restrictive regulations,” says Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) CEO Darryl Jones. “Our marketing strategy aims to leverage Israeli-branded products as fundamentally superior.”
In June, Israel’s Police Minister also backed the easing of enforcement of existing laws following a joint statement by the Prime Minister and Defense Minister outlining their intent to advance legislation “to resolve the issue of decriminalization and legalization”—ostensibly referring to recreational cannabis use in the country.
While the statements didn’t provide any specific timetable for the moves, experts believe that it could take about four months to advance legislation. The new rules could permit cannabis use for adults over 21 and cannabis sales would take place in designated shops. As in other markets, advertising would be restricted and an educational fund would be set up.
Isracann Biosciences, Israel’s only publicly-traded cannabis pure-play, has already tasked regional consultants with ensuring applications for an export permit will be made as soon as possible. Management believes that the country’s unique environment, advanced agro-economics and history of cannabinoid innovations will drive adoption.
“We are incredibly pleased by the recent news and are highly supportive of the initial proposals moving towards medical and recreational reform,” said Mr. Jones in a recent press release following the support for recreational legalization. “We look forward to building on this legislative framework as we continue to execute our strategic plans in the region.”
Click here to learn more about investing in the Israeli cannabis market
Finding the Best Opportunities
Canada’s cannabis market experienced a tumultuous couple of years. After U.S.-based demand failed to meet expectations, Canadian companies are hoping that the move into edibles, beverages and other “Cannabis 3.0” product formats will help spur domestic demand and pave the way for greater demand over the coming quarters.
The U.S. market continues to experience strong demand—even during the COVID-19 crisis—but the legal framework remains uncertain. While some states have legalized cannabis, there are high barriers to entry when it comes to licensing in some states and a chronic oversupply of the market in other states.
Europe remains one of the most promising bright spots for cannabis over the coming years. As legalization unfolds, investors may want to look for opportunities on the ground floor rather than trying to play catchup in more established markets. Countries like Israel could also see opportunities given their proximity to European end markets.
Click here to learn more about investing in the Israeli cannabis market
Looking Ahead
The COVID-19 crisis has impacted many parts of the global economy, but cannabis demand remains relatively stable. With many parts of the global economy opening back up, consumers are likely to return to medical and recreational cannabis markets and lawmakers may continue to explore opportunities to liberalize their drug laws.
Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is well-positioned to take advantage of the recovery as European end markets open up and export laws are liberalized to permit exports and the possibility of recreational legalization appears to be on the horizon. With existing operations in place, the company’s experienced management team is capable of scaling into new markets with innovative products.
For more information, visit the company’s website at www.isracann.com.
Isracann Company Contact:
Darryl Jones
CEO
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders.
Xphyto Therapeutics Corp. was created to bridge the gap between traditional cannabis-based medicine and modern scientific approaches to therapeutic validation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
